CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质瘤树突状细胞疫苗：从实验室到临床的挑战
英文原题：Dendritic cell vaccine of gliomas: challenges from bench to bed.
查看英文原题
Dendritic cell vaccine of gliomas: challenges from bench to bed.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质瘤占脑恶性肿瘤的大多数。作为胶质瘤中最恶性的亚型，胶质母细胞瘤（GBM）几乎无法通过传统疗法（手术联合放化疗）得到有效治疗，导致预后不良。同时，由于其“冷肿瘤”表型，GBM对多种免疫治疗均无应答。由于树突状细胞（DCs）具有启动T细胞应答的能力，其对抗肿瘤免疫至关重要。近年来，作为一种治疗手段，树突状细胞疫苗（DCV）得到了极大发展。然而，长期以来限制DCV应用的障碍仍有待解决。如下综述所述，本文描述了DCs在抗肿瘤免疫中的作用以及肿瘤微环境（TME）对DCs的抑制作用，总结了既往DCV治疗GBM的临床试验，并分析了DCV面临的挑战及可能的发展方向。
展开英文摘要原文
Gliomas account for the majority of brain malignant tumors. As the most malignant subtype of glioma, glioblastoma (GBM) is barely effectively treated by traditional therapies (surgery combined with radiochemotherapy), resulting in poor prognosis. Meanwhile, due to its "cold tumor" phenotype, GBM fails to respond to multiple immunotherapies. As its capacity to prime T cell response, dendritic cells (DCs) are essential to anti-tumor immunity. In recent years, as a therapeutic method, dendritic cell vaccine (DCV) has been immensely developed.
However, there have long been obstacles that limit the use of DCV yet to be tackled. As is shown in the following review, the role of DCs in anti-tumor immunity and the inhibitory effects of tumor microenvironment (TME) on DCs are described, the previous clinical trials of DCV in the treatment of GBM are summarized, and the challenges and possible development directions of DCV are analyzed.
论文信息
- 作者
- Zheng Y、Ma X、Feng S、Zhu H、Chen X、Yu X、Shu K、Zhang S
- 单位
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2023
- 原文标识
- PubMed 37781367 · DOI 10.3389/fimmu.2023.1259562
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →